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Abstract  
We performed quantitative analysis of 18F-flutemetamol PET-MR data in cerebral amyloid 
angiopathy. We showed consistent differences of pharmacokinetic estimates in cases versus 
controls for reduced against full PET acquisition. This may support future protocol optimisation 
in the clinical setting.   
Question  
PET imaging using 18F-flutemetamol may improve the detection of β-amyloid plaque density 
in cerebral amyloid angiopathy (CAA), versus the current clinical standard MRI biomarkers1.   
It is unknown whether pharmacokinetic estimates extracted by reduced (<90 min) acquisition 
time frames can robustly detect CAA.  
We performed quantitative analysis of dynamic PET-MR data to assess pharmacokinetic 
estimates in CAA patients against controls, for a reduced (60 min) against our full (120 min) 
PET acquisition.   
  
Methods 
We analysed 18F-flutemetamol PET-MRI (Siemens Biograph) dynamic data from a pilot 
cohort of 6 cases with probable CAA (age: 72±10 years) and 6 age-matched controls (69±10 
years) with no CAA, defined by the modified Boston criteria1. PET acquisition started at the 
time of tracer injection and lasted for 30 min, with a second period of data acquisition from 90 
to 120 min. An exponential function was fitted to each regional time-activity curve, to 
interpolate regional brain uptake from 30 to 90 min (Matlab).  
For both a reduced PET acquisition (RA-60 min) and our full PET acquisition (FA-120 min) 
time, four pharmacokinetic models were investigated across 12 brain atlas-derived time-
activity curves restricted to the cortical areas: 1-tissue compartment (1-TC), 2-tissue-4k 
compartment (2-TC), simplified reference tissue (SRTM) and full reference tissue model 
(FRTM)2 (PMOD). Statistical analysis was performed in R.       
Results  
Initially, all models were assessed in FA. 1-TC-derived volume of distribution (Vd: a tracer 
uptake estimate) and SRTM/FRTM-derived R1 (a relative cerebral blood flow estimate) were 
significantly higher and lower in patients against controls (P<0.01, Figure 1), respectively. No 
other significant differences were observed.  
Subsequently, all models were assessed in RA. Significant differences for 1-TC-derived Vd 
and SRTM/FRTM-derived R1 were consistent between patients and controls (P<0.01, Figure 
1).  
Conclusions 
We showed significant differences in pharmacokinetic estimates in patients with probable CAA 
versus controls, which were consistent when a reduced (60 min) PET acquisition time was 
used for analysis against our full (120 min) acquisition. This quantitative assessment may 
support careful optimisation of the minimum PET acquisition time required, for the accurate 
detection of CAA. Further pharmacokinetic assessments are currently performed in our full 
cohort (N=20) between reduced (<60 min) and full PET acquisition times.  
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Figure 1) (a) Time-activity curves from a patient with CAA (red) and a control (blue, dashed 
line shows the RA). (b, c) Mean (SD) values for patients and controls in FA (for 1-TC, 2-TC-
derived Vd and SRTM, FRTM-derived R1). (d, e) Similarly, mean (SD) values for patients and 
controls in RA. Significant differences are shown with *. FA: full PET acquisition time.  
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Figure footnote: Note that R1 reflects a normalised value (R1=K1/K1’, where K1: rate constant of tracer 
delivery from blood to tissue, K1’: rate constant of tracer delivery from blood to cerebellum reference region) 
